New Insights into the Regulation of Glucagon Secretion by Glucagon-like Peptide-1

J. Gromada; P. Rorsman

doi:10.1055/s-2004-826169

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2004; 36(11/12): 822-829
DOI: 10.1055/s-2004-826169

Review

New Insights into the Regulation of Glucagon Secretion by Glucagon-like Peptide-1

J. Gromada ¹ , P. Rorsman ²

¹Department of Pharmacology, University of Aarhus, Universitetsparken, Aarhus C, Denmark
²The Oxford Centre for Diabetes, Endocrinology and Metabolism, The Churchill Hospital, Oxford, UK

Abstract

Glucagon-like peptide-1 (GLP-1) is a potent incretin hormone currently under investigation for use as a novel therapeutic agent in the treatment of type 2 diabetes. One of several therapeutically important biological actions of GLP-1 in type 2 diabetic subjects is ability to induce strong suppression of glucagon secretion. The glucagonostatic action of GLP-1 results from its interaction with a specific G-protein coupled receptor resulting in the activation of adenylate cyclase and an increase in cAMP generation. In the pancreatic α-cell, cAMP, via activation of protein kinase A, interacts with a plethora of signal transduction processes including ion-channel activity and exocytosis of the glucagon-containing granules. In this short review, we will focus on recent advances in our understanding on the cellular mechanisms proposed to underlie the glucagonotropic action of GLP-1 and attempt to incorporate this knowledge into a working model for the control of glucagon secretion. Studies on the effects of GLP-1 on glucagon secretion are relevant to the pathogenesis of type 2 diabetes due to the likely contribution of hyperglucagonemia to impaired glucose tolerance in type 2 diabetes.

Key words

GLP-1 - Incretin - Glucagon - Alpha cell - Islet

Volltext

Referenzen

References

1 Reaven G M, Chen Y D, Golay A, Swislocki A L, Jaspan J B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987; 64 106-110
2 Shah P, Vella A, Basu A, Basu R, Schwenk W F, Rizza R A. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000; 85 4053-4059
3 Holst JJ. Enteroglucagon. Annu Rev Physiol. 1997; 59 257-271
4 Kieffer T J, Habener J F. The Glucagon-like peptides. Endocrine Rev. 1999; 20 876-913
5 Nauck M A, Heimesaat M K, Ørskov C, Holst J J, Ebert R, Creutzfeldt W. Preserved incretin activity og glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91 301-307
6 Nauck M A, Kleine N, Ørskov C, Holst J J, Willms B, Creutzfeldt W. Normalization of fastening hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993; 36 741-744
7 Nauck M A, Sauerwald A, Ritzel R, Holst J J, Schmiegel W H. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care. 1998; 21 1925-1931
8 Nauck M A, Weber I, Bach I, Richter S, Ørskov C, Holst J J, Schmiegel W. Normalization of fastening glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2-diabetic patients. Diabetic Med. 1998; 15 937-945
9 Creutzfeldt W OC, Ørskow C, Kleine N, Holst J J, Willms B, Nauck M A. Glucagonostatic actions and reduction of fasting hyperglycemia by Exogenous glucagon-like peptide 1(7-36) amide in type 1 diabetic patients. Diabetes Care. 1996; 19 580-586
10 Sloop K W, Cao J X-C, Siesky A M, Zhang H Y, Bodenmiller D M, Cox A L, Jacobs S J, Moyers J S, Owens R A, Showalter A D, Brenner M B, Raap A, Gromada J, Berridge B R, Monteith D KB, Porksen N, McKay R A, Monia B P, Bhanot S, Watts L M, Michael M D. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest. 2004; 113 1571-1581
11 Petersen K F, Sullivan J T. Effects of a novel glucagon receptor antagonist (Bay 27 - 9955) on glucagon-stimulated glucose production in humans. Diabetalogia. 2001; 44 2018-2024
12 Unson C G, Gurzenda E M, Merrifield R B. Biological activities of des-His1[Glu9] glucagon amide, a glucagon antagonist. Peptides. 1989; 10 1171-1177
13 Henquin J C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 2000; 49 1751-1760
14 Heimberg H, De Vos A, Moens K, Quartier E, Bouwens L, Pipeleers D, Van Schaftingen E, Madsen O, Schuit F. The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells. Proc Natl Acad Sci USA. 1996; 93 7036-7041
15 Heimberg H, De Vos A, Pipeleers D, Thorens B, Schuit F. Differences in glucose transporter gene expression between rat pancreatic alpha-and beta-cells are correlated to differences in glucose transport but not in glucose utilization. J Biol Chem. 1995; 270 8971-8975
16 Detimary P, Dejonghe S, Ling Z, Pipeleers D, Schuit F, Henquin J C. The changes in adenine nucleotides measured in glucose-stimulated rodent islets occur in beta cells but not in alpha cells and are also observed in human islets. J Biol Chem. 1998; 273 33 905-33 908
17 Gromada J, Ding W G, Barg S, Renström E, Rorsman P. Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors. Pflügers Arch. 1997; 434 515-524
18 Yoshimoto Y, Fukuyama Y, Horio Y, Inanobe A, Gotoh M, Kurachi Y. Somatostatin induces hyperpolarization in pancreatic islet alpha cells by activating a G protein-gated K⁺ channel. FEBS Lett. 1999; 444 265-269
19 Gopel S O, Kanno T, Barg S, Weng X G, Gromada J, Rorsman P. Regulation of glucagon release in mouse α-cells by KATP channels and inactivation of TTX-sensitive Na⁺ channels. J Physiol. 2000; 528 509-520
20 Rorsman P, Hellman B. Voltage-activated currents in guinea pig pancreatic alpha 2 cells. Evidence for Ca²⁺-dependent action potentials. J Gen Physiol. 1988; 91 223-242
21 Rorsman P. Two types of Ca²⁺ currents with different sensitivities to organic Ca²⁺ channel antagonists in guinea pig pancreatic alpha 2 cells. J Gen Physiol. 1988; 91 243-254
22 Barg S, Galvanovski J, Gopel S O, Rorsman P, Eliasson L. Tight coupling between electrical activity and exocytosis in mouse glucagon-secreting alpha-cells. Diabetes. 2000; 49 1500-1510
23 Gromada J, Ma X, Høy M, Bokvist K, Salehi A, Berggren P O, Rorsman P. ATP-Sensitive K+ channel-dependent regulation of glucagon release and electrical activity by glucose in wildtype and SUR1^-/-mouse α-cells. Diabetes. 2004; 53 (Suppl 3) 181-189
24 Bokvist K, Olsen H L, Hoy M, Gotfredsen C F, Holmes W F, Buschard K, Rorsman P, Gromada J. Characterisation of sulphonylurea and ATP-regulated K⁺ channels in rat pancreatic A-cells. Pflügers Arch. 1999; 438 428-436
25 Suzuki M, Fujikura K, Kotake K, Inagaki N, Seino S, Takata K. Immuno-localization of sulphonylurea receptor 1 in rat pancreas. Diabetologia. 1999; 42 1204-1211
26 Ishihara H, Maechler P, Gjinovci A, Herrera P L, Wollheim C B. Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat Cell Biol. 2003; 5 330-335
27 Liu Y J, Vieira E, Gylfe E. A store-operated mechanism determines the activity of the electrically excitable glucagons-secreting pancreatic α-cell. Cell Calcium. 2004; 35 357-365
28 Cejvan K, Coy D H, Efendic S. Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes. 2003; 52 1176-1181
29 Rorsman P, Berggren P O, Bokvist K, Ericson H, Mohler H, Östenson C G, Smith P A. Glucose-inhibition of glucagon secretion involves activation of GABA_A-receptor chloride channels. Nature. 1989; 341 233-236
30 Braun M, Wendt A, Birnir B, Broman J, Eliasson L, Galvanovskis J, Gromada J, Mulder H, Rorsman P. Regulated exocytosis of GABA-containing synaptic-like microvesicles in pancreatic β-cells. J Gen Physiol. 2004; 123 191-204
31 Wendt A, Birnir B, Buschard K, Gromada J, Salehi A, Sewing S, Rorsman P, Braun M. Glucose inhibition of glucagon secretion from rat α cells is mediated by GABA release from neighbouring β cells. Diabetes. 2004; 53 1038-1045
32 Michalik M, Erecinska M. GABA in pancreatic islets: metabolism and function. Biochem Pharmacol. 1992; 44 1-9
33 Ashcroft F M, Rorsman P. Electrophysiology of the pancreatic B-cell. Prog Biophys Mol Biol. 1989; 54 87-143
34 Ashcroft F, Rorsman P. Type 2 diabetes mellitus: not quite exciting enough?. Hum Mol Genet. 2004; 13 (1) R21-31
35 Fehmann H C, Habener J F. Functional receptors for the insulinotropic hormone glucagon-like peptide-1(7-37) on a somatostatin secreting cell line. FEBS. 1991; 279 335-340
36 Gros L, Demiprence E, Bataille D, Kervran A. Characterization of high-affinity receptors for glucagon-like peptide-1 (7-36)amide on a somatostatin-secreting cell line (RIN T3). Biomed Res. 1992; 13 143-150
37 Gros L, Thorens B, Bataille D, Kervran A. Glucagon-like peptide-1-(7-36)amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology. 1993; 133 631-638
38 Heller S R, Aponte G W. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7-36) amide. Am J Physiol. 1995; 269 G852-860
39 Heller S, Kieffer T J, Habener J F. Insulinotropic glucagon-like peptide 1 receptor expression in glucagon-producing α-cells of rat endocrine pancreas. Diabetes. 1997; 46 785-791
40 Ørskov C, Poulsen S. Glucagonlike peptide-1-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes. 1991; 40 1292-1296
41 Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, Schuit F. Expression and functional activity of glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes. 1996; 45 257-261
42 Ma X, Zhang Y, Gromada J, Sewing S, Berggren P O, Buschard K, Salehi A, Vikman J, Rorsman P, Eliasson L. Glucagon stimulates exocytosis in mouse and rat pancreatic α cells by binding to glucagon receptors. Mol Endocrinol. 2004; in press
43 Ding W G, Renström E, Rorsman P, Buschard K, Gromada J. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate Ca²⁺-induced secretion in rat α-cells by a protein kinase A-medicated mechanism. Diabetes. 1997; 46 792-800
44 Ashcroft F M, Gribble F M. ATP-sensitive K⁺ channels and insulin secretion. Their role in health and disease. Diabetologia. 1999; 42 903-919
45 Holz G G, Kühtreiber W M, Habener J F. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagons-like peptide-1 (7-37). Nature. 1993; 361 362-365
46 Gromada J, Bokvist K, Ding W G, Holst J J, Nielsen J H, Rorsman P. Glucagon-like peptide-1(7 - 36)amide stimulates exocytosis in human pancreatic B-cells by both proximal and distal regulatory steps in the stimulus-secretion coupling. Diabetes. 1998; 47 57-65
47 Light P E, Fox J EM, Riedel M J, Wheeler M B. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol Endocrinol. 2002; 16 2135-2144
48 Hoffmann D A, Johnson D. Downregulation of transient K⁺ channels in dentrites of hippocampal CA1 pyramidal neurons by activation of PKA and PKC. J Neurosci. 1998; 18 3521-3528
49 Anderson A E, Adams J P, Qian Y, Cook R G, Pfaffinger P J, Sweatt J D. Kv4.2 phosphorylation by cyclic AMP-dependent protein kinase. J Biol Chem. 2000; 275 5337-5346
50 Yuan L L, Adams J P, Swank M, Sweatt J D, Johnston D. Protein kinase modulation of dentritic K⁺ channels in hippocampus involves a mitogen-activated protein kinase pathway. J Neurosci. 2002; 22 4860-4868
51 Schrader L A, Anderson A E, Mayne A, Pfaffinger P J, Sweatt J D. PKA modulation of Kv4.2-encoded A-type potassium channels requires formation of a supramolecular complex. J Neurosci. 2002; 22 10123-10133
52 Adams J P, Anderson A E, Varga A W, Dineley K T, Cook R G, Pfaffinger P J, Sweatt J D. The A-type potassium channel kv4.2 is a substrate for the mitogen-activated protein kinase ERK. J Neurochem. 2000; 75 2277-2287
53 Gopel S, Zhang Q, Eliasson L, Ma X S, Galvanovskis J, Kanno T, Salehi A, Rorsman P. Capacitance measurements of exocytosis in mouse pancreatic alpha-, beta-and delta-cells within intact islets of Langerhans. J Physiol. 2004; 556 711-726
54 Gromada J, Høy M, Buschard K, Salehi A, Rorsman P. Somatostatin inhibits exocytosis in rat pancreatic α-cells by G_i2-dependent activation of calcineurin and depriming of secretory granules. J Physiol. 2001; 535 519-532
55 Bode H P, Moormann B, Dabew R, Göke B. Glucagon-like peptide 1 elevates cytosolic calcium in pancreatic β-cells independently of protein kinase A. Endocrinol. 1999; 140 3919-3927
56 Cullinan C A, Brady E J, Saperstein R, Leibowitz M D. Glucose-dependent alterations of intracellular free calcium by glucagons-like peptide-1(7 - 36amide) in individual ob/ob mouse β-cells. Cell Calcium. 1994; 15 391-400
57 Gromada J, Dissing S, Rorsman P. Desensitization of glucagon-like peptide 1 receptors in insulin-secreting βTC3 cells: role for PKA-independent mechanisms. Br J Pharmacol. 1996; 118 769-775
58 Holz G G, Leech C A, Heller R S, Castonguay M, Habener J F. cAMP-dependent mobilization of intracellular Ca²⁺ stores by activation of ryanodine receptors in pancreatic β-cells. A Ca²⁺ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J Biol Chem. 1999; 274 14 147-14 156
59 Kang G, Chepurny O G, Holz G G. cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca²⁺-induced Ca²⁺ release in INS-1 pancreatic β-cells. J Physiol. 2001; 536 375-385
60 Tsuboi T, Xavier G S, Holz G G, Jouaville L S, Thomas A P, Rutter G A. Glucagon-like peptide-1 mobilizes intracellular Ca²⁺ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 β-cells. Biochem J. 2003; 369 287-299
61 Yada T, Itoh K, Nakata M. Glucagon-like peptide-1-(7-36) amide and a rise in cyclic adenosine 3′,5′-monophosphate increase cytosolic free Ca²⁺ in rat pancreatic β-cells by enhancing Ca²⁺ channel activity. Endocrinol. 1993; 133 1685-1692
62 Gromada J, HÖy M, Buschard K, Salehi A, Rorsman P. Somatostatin inhibits exocytosis in rat pancreatic alpha-cells by G(i2)-dependent activation of calcineurin and depriming of secretory granules. J Physiol. 2001; 535 519-532
63 Rorsman P, Renström E. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 2003; 46 1029-1045
64 Ozaki N, Shibasaki T, Kashima Y, Mik T, Takahashi K, Ueno H, Sunaga Y, Yano H, Matsuura Y, Iwanaga T, Takai Y, Seino S. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol. 2000; 2 805-811
65 Shibasaki T, Sunaga Y, Fujimoto K, Kashima Y, Seino S. Interaction of ATP sensor, Ca²⁺ sensor, and voltage-dependent calcium channel and insulin granule exocytosis. J Biol Chem. 2003; 279 7956-7961
66 Eliasson L, Ma X, Renström E, Barg S, Berggren P O, Galvanovskis J, Gromada J, Jing X, Lundquist I, Salehi A, Sewing S, Rorsman P. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol. 2003; 121 181-197
67 Suzuki S, Kawai K, Ohashi S, Mukai H, Murayama Y, Yamashita K. Reduced insulinotropic effects of glucagonlike peptide 1-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas. Diabetes. 1990; 39 1320-1325
68 Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S. Glucanostatic and insulinotropic action of glucagonlike peptide 1-(7-36)-amide. Diabetes. 1989; 38 902-905
69 Kawai K, Suzuki S, Ohashi S, Mukai H, Ohmori H, Muayama Y, Yamashita K. Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinol. 1989; 124 1768-1773
70 Yamato E, Noma Y, Tahara Y, Ikegami H, Yamamoto Y, Cha T, Yoneda H, Ogihara T, Ohboshi C, Hirota M, Shima K. Suppression of synthesis and release of glucagon by glucagon-like peptide-1(7 - 36 amide) without affect on mRNA level in isolated rat islets. Biochem Biophys Res Commun. 1990; 2 431-437
71 Fehmann H C, Hering B J, Wolf M J, Brandhorst H, Brandhorst D, Bretzel R G, Federlin K, Göke B. The effect of glucagon-like peptide-1 (GLP-1) on hormone secretion form isolated human pancreatic islets. Pancreas. 1995; 11 196-200
72 Pipeleers D G, Schuit F C, Van Schravendijk C F, Van de Winkel M. Interplay of nutrients and hormones in regulation of glucagon release. Endocrinol. 1985; 117 817-823
73 Nauck M A, Heimesaat M M, Behle K, Holst J J, Nauck M S, Ritzel R, Hufner M, Schmiegel W H. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002; 87 1239-1246
74 Dinneen S F. The postrandial state. Mechanisms of glucose intolenrance. Diabet Med. 1997; 14 suppl 3 S19-24
75 Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol. 1999; 277 E283-290

J. Gromada

Lilly Research Laboratories

Essener Straße 93 · 22419 Hamburg · Germany ·

Telefon: +49 (40) 527 24 323

Fax: +49 (40) 527 24 615

eMail: gromada@lilly.com